Login
Home / IMM.AX : ASX
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Immutep Limited

AUD 0.05 -$0.38 (-89.07%)
ASX · 16 Sep 2026 06:10 UTC
Previous Close
AUD 0.04
Day Range
AUD 0.04AUD 0.05
Year Range
AUD 0.03AUD 0.47
Market Cap
69.26M
AVG Volume
13.83M
Trailing/Forward PE
-0.87/-
PEG ratio
-0.03
Dividend Yield
-
Next Earnings Date
2027-02-25
Primary Exchange
Australian Securities ExchangeAU
Revenue (AUD)
05M10M15M22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Net Income (AUD)
-60M-40M-20M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Operating Income (AUD)
-80M-60M-40M-20M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
EBITDA (AUD)
-60M-40M-20M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Cash Flows (AUD)
-40M-30M-20M-10M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
EPS (AUD)
-0.04-0.03-0.02-0.01022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Expenses (AUD)
020M40M60MR&DSG&ACapex22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Cash & Debt (AUD)
050M100M150M200MCashLong Term DebtShort Term Debt22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Debt ratios
012322 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Margins
-2000%-1500%-1000%-500%0%500%22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Return on Capital
-60%-40%-20%0%22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Shares Outstanding
0500M1B1.5B22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Book Value Per Share (AUD)
00.050.10.150.222 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Total Assets (AUD)
0100M200M300M22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
Free Cash Flow Yield
-200%-150%-100%-50%0%med -16.1%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Sales
020406080med 44.12Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Price to Book
0246med 2.08Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
Immutep Limited
IMM.AX
Stockpicker

Video analysis: IMM.AX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: IMM.AX

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

globenewswire.com · 24 Jul 2026

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23-27 October 2026 in Madrid, Spain.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.